Industry Newsantibody drug conjugateoncologycytomxclinical trials
CytomX Gains Analyst Price Target Upgrades
5.1
On March 18, Jefferies and Guggenheim raised price targets on CytomX Therapeutics to $16 and $15, respectively, after encouraging Phase 1 data for Varseta‑M in late‑line metastatic colorectal cancer. Both firms increased confidence—Guggenheim raised probability of success to 60% from 30%—and cited a potential later‑line commercial opportunity exceeding $1 billion, supporting a favorable investor risk‑reward outlook.
Key Points
- 1Reports: Jefferies and Guggenheim raise CytomX price targets to $16 and $15.
- 2Highlights: Phase 1 Varseta‑M data showed strong efficacy, raising probability of success to 60%.
- 3Implication: Analysts estimate over $1 billion later‑line market, supporting favorable investor risk‑reward.
Scoring Rationale
Analyst upgrades and encouraging Phase 1 data drive relevance; limited novelty and low relevance to AI/ML reduces impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
